vebreltinib
Phase 2- Indications
- Cancer
Company intelligence / Profile preview
Apollon's needle-free CGM device ("MOGLU") uses miniaturized Raman spectroscopy to measure blood glucose continuously and non-invasively. Early results indicate accuracy comparable to traditional CGMs with improved comfort and cost-effectiveness. Ongoing clinical studies are being conducted in collaboration with MIT; human data release anticipated soon. The company claims the device meets FDA standards for accuracy and safety.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Apollon Inc..